文献速递胸部肿瘤

美国EGFR突变晚期非小细胞肺癌一线奥希替尼治疗的总生存:整合临床与生物标志物数据的队列研究

Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
PubMed 文献 · J Thorac Oncol · 2025-05-02

该回顾性新用药者队列研究利用美国三个数据库,纳入2018年4月1日至2022年10月30日一线奥希替尼单药治疗的1323例晚期EGFR突变非小细胞肺癌患者,中位随访20个月,中位真实世界总生存期为28.6个月(95%CI 26.8-30.9),95%患者至少有一个高风险因素,33%未接受二线治疗。

要点

  • 中位真实世界总生存期为28.6个月(95%CI 26.8-30.9)。
  • ECOG≥2、脑转移、肝转移、TP53共突变患者的中位rwOS分别为18.1、24.3、19.3、25.7个月。
  • 95%患者至少有一个高风险因素,33%未接受二线治疗。

核心结论

  • 尽管酪氨酸激酶抑制剂治疗取得进展,晚期EGFR突变非小细胞肺癌患者的长期生存仍然较差。
  • 几乎所有患者都存在死亡风险因素,且三分之一未接受二线治疗。

研究设计与样本

  • 这是一项回顾性新用药者队列研究,使用ConcertAI、Flatiron Clinical-Genomics和COTA数据库的电子记录。
  • 纳入2018年4月1日至2022年10月30日一线起始奥希替尼单药治疗的晚期或转移性EGFR突变非小细胞肺癌患者,随访至死亡或2023年10月31日。
  • 共纳入1323例患者,中位随访20个月,中位年龄70岁(范围35-89岁)。

主要发现

  • 中位真实世界总生存期为28.6个月(95%CI 26.8-30.9)。
  • 高风险亚组中位rwOS:ECOG评分≥2者为18.1个月,脑转移者为24.3个月,肝转移者为19.3个月,TP53共突变者为25.7个月。
  • ECOG≥2、脑转移、肝转移、TP53共突变的患病率分别为17%、36%、15%、63%。
  • 高风险因素患者的死亡风险显著更高(所有p≤0.011)。
  • 58%患者生存至2年,18%生存至5年,33%未接受二线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with NSCLC harboring EGFR mutations (EGFRm) have high mortality. The third-generation tyrosine kinase inhibitor, osimertinib, is approved for first-line EGFRm NSCLC. We used longitudinal U.S. medical oncology databases to evaluate real-world overall survival (rwOS) and prognostic risk factor groups in advanced EGFRm NSCLC treated with first-line osimertinib. METHODS: This retrospective, new-user cohort study used electronic records from ConcertAI, Flatiron Clinical-Genomics, and COTA databases. Patients with advanced or metastatic EGFRm NSCLC initiating osimertinib monotherapy in first line between April 1, 2018, and October 30, 2022, were included. Follow-up was until death or October 31, 2023. rwOS was estimated using the Kaplan-Meier method. Risk factors were evaluated using multivariate analysis. RESULTS: A total of 1323 patients were included with a median follow-up of 20 months. Median age was 70 (range 35-89) years. Median rwOS was 28.6 months (95% confidence interval 26.8-30.9). In high-risk subgroups, median rwOS (mo) was 18.1 in patients with Eastern Cooperative Oncology Group score greater than or equal to 2, 24.3 with brain metastases, 19.3 with liver metastases, and 25.7 with TP53 co-mutation. In total, 95% of patients had at least one high-risk factor. Prevalence of Eastern Cooperative Oncology Group greater than or equal to 2 was 17%, brain metastases 36%, liver metastases 15%, and TP53 co-mutation 63%. Risk of death was significantly higher in patients with high-risk factors (p ≤ 0.011 for all). In total, 58% of patients survived to 2 years, 18% to 5 years, and 33% did not receive second-line therapy. CONCLUSION: Despite advances in tyrosine kinase inhibitor treatments, long-term survival of patients with advanced EGFRm NSCLC remains poor. Nearly all patients had risk factors for mortality and one-third did not receive second-line therapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Sabari JK, Yu HA, Mahadevia PJ, et al. Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States. J Thorac Oncol. 2025. PMID: 40320171. doi:10.1016/j.jtho.2025.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。